Skip to main content

Animations

MJFF Publications

6211 - 6220 of 9145 Results
Title
Year
  • Year
  • 2020
  • 2021
  • 2015
  • 2020
  • 2013
  • 2020
  • 2019
  • 2023
  • 2021
  • 2016
  • Summary Details
    OPEN
    Title: Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2020.4725
    Citation Count: 146
  • Summary Details
    OPEN
    Title: Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.28738
    Citation Count: 116
  • Summary Details
    OPEN
    Title: The Cooperative Health Research in South Tyrol (CHRIS) study: rationale, objectives, and preliminary results
    Journal Name: Journal of Translational Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s12967-015-0704-9
    Citation Count: 105
  • Summary Details
    OPEN
    Title: The Parkinson's Disease Genome‐Wide Association Study Locus Browser
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.28197
    Citation Count: 104
  • Which dyskinesia scale best detects treatment response?
    2013
    Summary Details
    RESTRICTED
    Title: Which dyskinesia scale best detects treatment response?
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.25321
    Citation Count: 89
  • Summary Details
    OPEN
    Title: Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross‐Sectional Study
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.27989
    Citation Count: 85
  • Summary Details
    OPEN
    Title: Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.27818
    Citation Count: 86
  • Summary Details
    OPEN
    Title: Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update
    Journal Name: Journal of Parkinson’s Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.3233/jpd-239901
    Citation Count: 89
  • Summary Details
    OPEN
    Title: The Mutation Matters: CSF Profiles of GCase, Sphingolipids, α‐Synuclein in PDGBA
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.28472
    Citation Count: 76
  • Summary Details
    OPEN
    Title: Large-Scale Wearable Sensor Deployment in Parkinson’s Patients: The Parkinson@Home Study Protocol
    Journal Name: JMIR Research Protocols
    Publisher: JMIR Publications Inc.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.2196/resprot.5990
    Citation Count: 73
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.